| Literature DB >> 29269410 |
Hugues de Boussac1, Claire Gondeau1, Philippe Briolotti1, Cédric Duret1, Fridolin Treindl1, Michael Römer1, Jean-Michel Fabre1, Astrid Herrero1, Jeanne Ramos1, Patrick Maurel1, Markus Templin1, Sabine Gerbal-Chaloin1, Martine Daujat-Chavanieu2.
Abstract
Growth factors have key roles in liver physiology and pathology, particularly by promoting cell proliferation and growth. Recently, it has been shown that in mouse hepatocytes, epidermal growth factor receptor (EGFR) plays a crucial role in the activation of the xenosensor constitutive androstane receptor (CAR) by the antiepileptic drug phenobarbital. Due to the species selectivity of CAR signaling, here we investigated epidermal growth factor (EGF) role in CAR signaling in primary human hepatocytes. Primary human hepatocytes were incubated with CITCO, a human CAR agonist, or with phenobarbital, an indirect CAR activator, in the presence or absence of EGF. CAR-dependent gene expression modulation and PXR involvement in these responses were assessed upon siRNA-based silencing of the genes that encode CAR and PXR. EGF significantly reduced CAR expression and prevented gene induction by CITCO and, to a lower extent, by phenobarbital. In the absence of EGF, phenobarbital and CITCO modulated the expression of 144 and 111 genes, respectively, in primary human hepatocytes. Among these genes, only 15 were regulated by CITCO and one by phenobarbital in a CAR-dependent manner. Conversely, in the presence of EGF, CITCO and phenobarbital modulated gene expression only in a CAR-independent and PXR-dependent manner. Overall, our findings suggest that in primary human hepatocytes, EGF suppresses specifically CAR signaling mainly through transcriptional regulation and drives the xenobiotic response toward a pregnane X receptor (PXR)-mediated mechanism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29269410 DOI: 10.1124/dmd.117.078683
Source DB: PubMed Journal: Drug Metab Dispos ISSN: 0090-9556 Impact factor: 3.922